CIK 0001563665
- Non-accelerated filer
- Smaller reporting company
Harvard Apparatus Regenerative Technology, Inc.
Sign in to watch- Ticker
- HRGN
- Exchange
- OTC
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 455210462
- Phone
- +1 774-233-7300
- Business address
- 84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON, MA, 01746
- Former names
- Biostage, Inc.
- 4 Open-market buy Chief Financial Officer bought 15,000 shares at $1.32 ($19,800)
- 4 Open-market buy Director bought 25,000 shares at $1.34 ($33,500)
- 4 Open-market buy Chief Medical Officer bought 9,500 shares at an average $1.29 ($12,210)
- 4 Other acquisition Chief Medical Officer acquired 10,284 shares (other)
- 4/A Open-market buy Chief Medical Officer bought 2,500 shares at $0.96 ($2,400)
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Chief Medical Officer bought 2,500 shares at $0.96 ($2,400)
- 4 Open-market buy Chief Financial Officer bought 10,000 shares at $0.88 ($8,800)
- 4 Open-market buy Director bought 12,000 shares at $0.83 ($9,960)
- 4 Open-market buy Chief Financial Officer bought 100,000 shares at an average $0.66 ($65,500)
- 4 Open-market buy President and CEO bought 31,300 shares at an average $0.74 ($23,025)
- 3/A Insider 3/A
- 4 Open-market buy President and CEO bought 30,000 shares at an average $4.21 ($126,400)
- 4 Open-market buy Director bought 1,000 shares at $2.13 ($2,130)
- 4 Open-market buy Director bought 23,400 shares at $1.98 ($46,332)
- 4 Open-market buy Director bought 1,000 shares at $1.95 ($1,950)
- 4 Open-market buy Interim CEO & CFO bought 16,000 shares at an average $1.85 ($29,670)
- 4 Open-market buy Director bought 26,600 shares at $1.81 ($48,146)
- 4 Open-market buy Director bought 10,000 shares at $1.67 ($16,700)
- 4 Open-market buy Interim CEO & CFO bought 5,000 shares at $1.91 ($9,550)
Page 10 of 12 · 235 filings